U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H31FO6
Molecular Weight 434.4987
Optical Activity UNSPECIFIED
Defined Stereocenters 8 / 8
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BETAMETHASONE ACETATE

SMILES

C[C@@]1([H])C[C@@]2([H])[C@]3([H])CCC4=CC(=O)C=C[C@]4(C)[C@]3([C@]([H])(C[C@]2(C)[C@]1(C(=O)COC(=O)C)O)O)F

InChI

InChIKey=AKUJBENLRBOFTD-QZIXMDIESA-N
InChI=1S/C24H31FO6/c1-13-9-18-17-6-5-15-10-16(27)7-8-21(15,3)23(17,25)19(28)11-22(18,4)24(13,30)20(29)12-31-14(2)26/h7-8,10,13,17-19,28,30H,5-6,9,11-12H2,1-4H3/t13-,17-,18-,19-,21-,22-,23-,24-/m0/s1

HIDE SMILES / InChI

Molecular Formula C24H31FO6
Molecular Weight 434.4987
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 8 / 8
E/Z Centers 0
Optical Activity UNSPECIFIED

Betamethasone and its derivatives, betamethasone sodium phosphate and betamethasone acetate, are synthetic glucocorticoids. Used for its antiinflammatory or immunosuppressive properties, betamethasone is combined with a mineralocorticoid to manage adrenal insufficiency and is used in the form of betamethasone benzoate, betamethasone dipropionate, or betamethasone valerate for the treatment of inflammation due to corticosteroid-responsive dermatoses. Betamethasone and clotrimazole are used together to treat cutaneous tinea infections. Betamethasone is a glucocorticoid receptor agonist. This leads to changes in genetic expression once this complex binds to the GRE. The antiinflammatory actions of corticosteroids are thought to involve lipocortins, phospholipase A2 inhibitory proteins which, through inhibition arachidonic acid, control the biosynthesis of prostaglandins and leukotrienes. The immune system is suppressed by corticosteroids due to a decrease in the function of the lymphatic system, a reduction in immunoglobulin and complement concentrations, the precipitation of lymphocytopenia, and interference with antigen-antibody binding. Betamethasone binds to plasma transcortin, and it becomes active when it is not bound to transcortin.Betamethasone is used for: treating certain conditions associated with decreased adrenal gland function. It is used to treat severe inflammation caused by certain conditions, including severe asthma, severe allergies, rheumatoid arthritis, ulcerative colitis, certain blood disorders, lupus, multiple sclerosis, and certain eye and skin conditions.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
1.3 nM [EC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-2.74838405E11
Primary
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-2.74838405E11
Primary
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-2.74838405E11
Primary
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-2.74838405E11
Palliative
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-2.74838405E11
Primary
CELESTONE SOLUSPAN

Approved Use

When oral therapy is not feasible, the intramuscular use of CELESTONE SOLUSPAN Injectable Suspension is indicated as follows: Allergic States Control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. Dermatologic Diseases Bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (Stevens-Johnson syndrome). Endocrine Disorders Congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. Gastrointestinal Diseases To tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. Hematologic Disorders Acquired (autoimmune) hemolytic anemia, Diamond-Blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. Miscellaneous Trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. Neoplastic Diseases For palliative management of leukemias and lymphomas. Nervous System Acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. Ophthalmic Diseases Sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. Renal Diseases To induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. Respiratory Diseases Berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. Rheumatic Disorders As adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). For the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus.

Launch Date

-2.74838405E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
76.8 ng/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
67.6 ng/mL
6 mg single, intramuscular
dose: 6 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
101 ng/mL
8 mg single, intravenous
dose: 8 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
796 ng × h/mL
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
811 ng × h/mL
6 mg single, intramuscular
dose: 6 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
46.3 μg × min/mL
8 mg single, intravenous
dose: 8 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
13.9 h
6 mg single, oral
dose: 6 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
10.2 h
6 mg single, intramuscular
dose: 6 mg
route of administration: Intramuscular
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE
food status: FASTED
335 min
8 mg single, intravenous
dose: 8 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
36%
8 mg single, intravenous
dose: 8 mg
route of administration: Intravenous
experiment type: SINGLE
co-administered:
BETAMETHASONE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
7.2 mg 1 times / day multiple, oral
Highest studied dose
Dose: 7.2 mg, 1 times / day
Route: oral
Route: multiple
Dose: 7.2 mg, 1 times / day
Sources:
unhealthy, adult
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >10 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no [IC50 >133 uM]
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
yes
Drug as victimTox targets
PubMed

PubMed

TitleDatePubMed
Treatment of psoriasis with a new combination of calcipotriol and betamethasone dipropionate: a flow cytometric study.
2001
Clinical evaluation of human placental extract (placentrex) in radiation-induced oral mucositis.
2001
Clinical experience with topical calcitriol (1,25-dihydroxyvitamin D3) in psoriasis.
2001 Apr
Efficacy and tolerance of topical calcitriol 3 microg g(-1) in psoriasis treatment: a review of our experience in Poland.
2001 Apr
[Analysis of selected parameters of maternal and fetal status during stimulation of fetal lung maturation].
2001 Apr
A topical steroid without an antibiotic cures external otitis efficiently: a study in an animal model.
2001 Aug
Severe oral manifestations of chronic graft-vs.-host disease.
2001 Aug
The delivery of topical nasal sprays and drops to the middle meatus: a semiquantitative analysis.
2001 Aug
Single versus repeated-course antenatal corticosteroids: outcomes in singleton and multiple-gestation pregnancies.
2001 Aug
Most patients overdose on topical nasal corticosteroid drops: an accurate delivery device is required.
2001 Aug
Infantile acute hemorrhagic edema of the skin.
2001 Aug
Multiple courses of antenatal betamethasone and cognitive development of mice offspring.
2001 Aug
Painless thyroiditis induced by the cessation of betamethasone.
2001 Aug
Evaluation of the inhibitory activity of topical indomethacin, betamethasone valerate and emollients on UVL-induced inflammation by means of non-invasive measurements of the skin elasticity.
2001 Aug
Lichen planus-like eruption following autologous bone marrow transplantation for chronic myeloid leukaemia.
2001 Aug
Repeated prenatal corticosteroid administration delays astrocyte and capillary tight junction maturation in fetal sheep.
2001 Aug
Differentiation between dexamethasone and betamethasone in a mixture using multiple mass spectrometry.
2001 Aug 10
Comparative effects of calcipotriol and betamethasone 17-valerate solution in the treatment of seborrhoeic dermatitis of the scalp.
2001 Jan
Acute paronychia: comparative treatment with topical antibiotic alone or in combination with corticosteroid.
2001 Jan
Topical therapy with fluorinated and non-fluorinated corticosteroids in patients with atopic dermatitis.
2001 Jan
Systemic ketoconazole for yeast allergic patients with atopic dermatitis.
2001 Jan
Severe vulvovaginitis associated with intravaginal nystatin therapy.
2001 Jul
The interactive effects of endotoxin with prenatal glucocorticoids on short-term lung function in sheep.
2001 Jul
An evidence-based assessment of occlusal adjustment as a treatment for temporomandibular disorders.
2001 Jul
The effect of betamethasone versus dexamethasone on fetal biophysical parameters.
2001 Jul
Nonoperative treatment of an interosseous ganglion cyst.
2001 Jul
Valsalva retinopathy-like hemorrhage associated with combined trabeculotomy-trabeculectomy in a patient with developmental glaucoma.
2001 Jul-Aug
Tocolytic magnesium sulfate toxicity and unexpected neonatal death.
2001 Jun
Deleterious effects of local corticosteroid injections on the Achilles tendon of rats.
2001 Jun
Preliminary results of a pilot study investigating the potential of salivary cortisol measurements to detect occult adrenal suppression secondary to steroid nose drops.
2001 Jun
Inhibitory effects of anti-inflammatory drugs on interleukin-6 bioactivity.
2001 Jun
A prospective, randomized trial comparing the efficacy of dexamethasone and betamethasone for the treatment of antepartum HELLP (hemolysis, elevated liver enzymes, and low platelet count) syndrome.
2001 Jun
Tacrolimus suppressed the production of cytokines involved in atopic dermatitis by direct stimulation of human PBMC system. (Comparison with steroids).
2001 Jun
Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids.
2001 Mar
Investigation of some commercially available spacer devices for the delivery of glucocorticoid steroids from a pMDI.
2001 May
[Pemphigoid gestationis: treatment by topical class I corticosteroid].
2001 May
Dermatitis during radiation for vulvar carcinoma: prevention and treatment with granulocyte-macrophage colony-stimulating factor impregnated gauze.
2001 May-Jun
Comparison of intramuscular betamethasone and oral prednisone in the prevention of relapse of acute asthma.
2001 May-Jun
Lumbar facet joint synovial cyst: percutaneous treatment with steroid injections and distention--clinical and imaging follow-up in 12 patients.
2001 Oct
Use of antenatal steroids to counteract the negative effects of tracheal occlusion in the fetal lamb model.
2001 Oct
Single vs weekly courses of antenatal corticosteroids for women at risk of preterm delivery: A randomized controlled trial.
2001 Oct 3
Growth and development of children to 4 years of age after repeated antenatal steroid administration.
2001 Sep
Repeated antenatal corticosteroid treatments. Do they reduce neonatal morbidity?
2001 Sep
Effects of antiinflammatory drugs on migration of the rabbit corneal epithelium.
2001 Sep
Manipulation under anesthesia for frozen shoulder with and without steroid injection.
2001 Sep
Multiple courses of antenatal steroids: risks and benefits.
2001 Sep
Fetal monkey surfactants after intra-amniotic or maternal administration of betamethasone and thyroid hormone.
2001 Sep
Treatment of childhood phimosis with a moderately potent topical steroid.
2001 Sep
Programming effects in sheep of prenatal growth restriction and glucocorticoid exposure.
2001 Sep
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment:: Can also be used topically https://medlineplus.gov/druginfo/meds/a682799.html
The initial dosage of parenterally administered Betamethasone Sodium Phosphate and Betamethasone Acetate Injectable Suspension may vary from 0.25 to 9 mg per day depending on the specific disease entity being treated. However, in certain overwhelming, acute, life-threatening situations, administrations in dosages exceeding the usual dosages may be justified and may be in multiples of the oral dosages. In the treatment of acute exacerbations of multiple sclerosis, daily doses of 30 mg of betamethasone for a week followed by 12 mg every other day for 1 month are recommended.In pediatric patients, the initial dose of betamethasone may vary depending on the specific disease entity being treated. The range of initial doses is 0.02 to 0.3 mg/kg/day in three or four divided doses (0.6 to 9 mg/m2bsa/day).
Route of Administration: Parenteral
In Vitro Use Guide
Betamethasone (10(-6)M) significantly reduced both pH 6-induced bronchial response and CGRP-like immunoreactivity overflow in guinea-pig isolated perfused lung.
Substance Class Chemical
Created
by admin
on Fri Jun 25 20:46:38 UTC 2021
Edited
by admin
on Fri Jun 25 20:46:38 UTC 2021
Record UNII
TI05AO53L7
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BETAMETHASONE ACETATE
EP   GREEN BOOK   JAN   MART.   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
Common Name English
BETAMETHASONE ACETATE [EP]
Common Name English
BETAMETHASONE ACETATE [WHO-DD]
Common Name English
BETAMETHASONE ACETATE [GREEN BOOK]
Common Name English
DEXAMETHASONE ACETATE IMPURITY D [EP]
Common Name English
OSURNIA COMPONENT BETAMETHASONE ACETATE
Brand Name English
BETAMETHASONE ACETATE COMPONENT OF OSURNIA
Brand Name English
9-FLUORO-11.BETA.,17,21-TRIHYDROXY-16.BETA.-METHYLPREGNA-1,4-DIENE-3,20-DIONE 21-ACETATE
Systematic Name English
BETAMETHASONE ACETATE [USP-RS]
Common Name English
CELESTONE SOLUSPAN COMPONENT BETAMETHASONE ACETATE
Common Name English
BETAMETHASONE VALERATE IMPURITY A [EP]
Common Name English
BETAMETHASONE 21-ACETATE
MI  
Common Name English
BETAMETHASONE ACETATE [MART.]
Common Name English
NSC-759196
Code English
PREGNA-1,4-DIENE-3,20-DIONE, 9-FLUORO-11,17-DIHYDROXY-16-METHYL-21-(ACETYLOXY)-, (11.BETA.,16.BETA.)-
Systematic Name English
BETAMETHASONE ACETATE [USP]
Common Name English
BETAMETHASONE ACETATE [ORANGE BOOK]
Common Name English
BETAMETHASONE ACETATE [EP MONOGRAPH]
Common Name English
BETAMETHASONE ACETATE COMPONENT OF CELESTONE SOLUSPAN
Common Name English
BETAMETHASONE ACETATE [JAN]
Common Name English
BETAMETHASONE ACETATE [VANDF]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C521
Created by admin on Fri Jun 25 20:46:38 UTC 2021 , Edited by admin on Fri Jun 25 20:46:38 UTC 2021
CFR 21 CFR 524.955
Created by admin on Fri Jun 25 20:46:38 UTC 2021 , Edited by admin on Fri Jun 25 20:46:38 UTC 2021
CFR 21 CFR 522.161
Created by admin on Fri Jun 25 20:46:38 UTC 2021 , Edited by admin on Fri Jun 25 20:46:38 UTC 2021
Code System Code Type Description
ECHA (EC/EINECS)
213-578-6
Created by admin on Fri Jun 25 20:46:38 UTC 2021 , Edited by admin on Fri Jun 25 20:46:38 UTC 2021
PRIMARY
ChEMBL
CHEMBL1200538
Created by admin on Fri Jun 25 20:46:38 UTC 2021 , Edited by admin on Fri Jun 25 20:46:38 UTC 2021
PRIMARY
CAS
987-24-6
Created by admin on Fri Jun 25 20:46:38 UTC 2021 , Edited by admin on Fri Jun 25 20:46:38 UTC 2021
PRIMARY
FDA UNII
TI05AO53L7
Created by admin on Fri Jun 25 20:46:38 UTC 2021 , Edited by admin on Fri Jun 25 20:46:38 UTC 2021
PRIMARY
RXCUI
1516
Created by admin on Fri Jun 25 20:46:38 UTC 2021 , Edited by admin on Fri Jun 25 20:46:38 UTC 2021
PRIMARY RxNorm
DRUG CENTRAL
349
Created by admin on Fri Jun 25 20:46:38 UTC 2021 , Edited by admin on Fri Jun 25 20:46:38 UTC 2021
PRIMARY
EVMPD
SUB00780MIG
Created by admin on Fri Jun 25 20:46:38 UTC 2021 , Edited by admin on Fri Jun 25 20:46:38 UTC 2021
PRIMARY
DRUG BANK
DBSALT001422
Created by admin on Fri Jun 25 20:46:38 UTC 2021 , Edited by admin on Fri Jun 25 20:46:38 UTC 2021
PRIMARY
MERCK INDEX
M2452
Created by admin on Fri Jun 25 20:46:38 UTC 2021 , Edited by admin on Fri Jun 25 20:46:38 UTC 2021
PRIMARY Merck Index
NCI_THESAURUS
C65256
Created by admin on Fri Jun 25 20:46:38 UTC 2021 , Edited by admin on Fri Jun 25 20:46:38 UTC 2021
PRIMARY
EPA CompTox
987-24-6
Created by admin on Fri Jun 25 20:46:38 UTC 2021 , Edited by admin on Fri Jun 25 20:46:38 UTC 2021
PRIMARY
USP_CATALOG
1067001
Created by admin on Fri Jun 25 20:46:38 UTC 2021 , Edited by admin on Fri Jun 25 20:46:38 UTC 2021
PRIMARY USP-RS
PUBCHEM
443967
Created by admin on Fri Jun 25 20:46:38 UTC 2021 , Edited by admin on Fri Jun 25 20:46:38 UTC 2021
PRIMARY
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (UV)
EP
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
Related Record Type Details
ACTIVE MOIETY